Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec 20;1(1):e8.
doi: 10.1097/HS9.0000000000000008. eCollection 2017 Dec.

Immunotherapy Frontiers in Hematology

Simon Hallam  1
Affiliations
Editorial

Immunotherapy Frontiers in Hematology

Simon Hallam. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have indicated they have no potential conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Frontiers in immunotherapy. A. Checkpoint inhibition targets the inhibitory immune checkpoints which limit T-cell activation. Antibodies targeting PD-1, PD-L1 and CTLA4 are all in clinical use. B. Bi-specific T-cell engagers, such as blinatumomab, are fusion proteins consisting of two linked single chain variable fragments. One is directed at a tumor associated antigen, and the other recruits T-cells through binding to the CD3 domain of the T-cell receptor. C. Chimeric antigen receptors consist of an extracellular, antibody derived, antigen recognition domain which targets a tumor associated antigen, a transmembrane domain, and an intracellular co-stimulatory domain linked to the signaling domain of the T cell receptor. Common co-stimulatory domains are CD28 and 4-1BB. MHC = Major histocompatability complex, PD-1 = Programmed cell death protein 1, PD-L1 = Programmed death ligand 1, TAA = Tumor associated antigen, TCR = T-cell receptor.
See this image and copyright information in PMC

References

    1. Vardhana S, Younes A. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica 2016; 101:794–802. - PMC - PubMed
    1. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017; 376:836–847. - PMC - PubMed
    1. Rosenbaum L. Tragedy, perseverance, and chance—the story of CAR-T therapy. N Engl J Med 2017; 377:1313–1315. - PubMed
    1. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 2017; doi: 10.1038/nrclinonc.2017.128. [Epub ahead of print]. - PubMed
    1. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116:4099–4102. - PMC - PubMed

Publication types